Myelin is a multilamellar, lipid-rich membrane that insulates axons in the vertebrate nervous system to facilitate the rapid conduction of action potentials^[@R1]^. In addition, myelinating glia promote neuronal health by providing vital trophic support to the axons they ensheath^[@R2],\ [@R3]^. Myelin is generated by specialized glial cells -- Schwann cells (SCs) in the peripheral nervous system (PNS) and oligodendrocytes in the central nervous system (CNS)^[@R1]^. Oligodendrocytes form the myelin sheath by extending and iteratively wrapping their plasma membranes around axons, while glial cell cytoplasm is extruded to ultimately form compact myelin^[@R4]^. Impaired myelination causes debilitating symptoms in many severe neurological disorders such as multiple sclerosis, and loss of mature oligodendrocytes and myelin can lead to neuronal death and eventual paralysis. Therefore, continued research to uncover new pathways that promote oligodendrocyte development and remyelination is essential^[@R5]^.

Although myelin is required for human life, the molecular mechanisms that underlie glial cell development and myelination are incompletely understood. Previous studies indicate that extracellular matrix proteins and their receptors, in addition to intracellular signal transduction cascades, are essential for proper development of myelinating glial cells^[@R6]--[@R7]^. For this reason, adhesion G protein-coupled receptors (aGPCRs) represent good candidate regulators of glial cell development and myelination because they are purported to regulate both cell-cell and cell-matrix interactions as well as signal transduction by heterotrimeric G proteins^[@R8]^, and recent studies implicate aGPCRs as important regulators of myelination^[@R9]--[@R13]^. Indeed, the aGPCR Gpr126 is essential for SC, but not oligodendrocyte, myelination^[@R10]--[@R13]^.

aGPCRs are the second largest class of GPCRs, but remain relatively understudied due to their structural complexity. In addition to the canonical seven-transmembrane (7TM) domain common to all GPCRs that usually facilitates intracellular signaling, aGPCRs are characterized by the presence of a very large N-terminal domain rich in functional motifs associated with cell-cell and cell-matrix adhesion, which is separated from the 7TM by a GPCR proteolytic site (GPS)^[@R14]^. The GPS motif is encompassed by a larger GPCR autoproteolysis-inducing (GAIN) domain^[@R15]^. Together, these domains are required for autoproteolytic cleavage of the N-terminus from the C-terminus, a process that may be required for proper intracellular aGPCR trafficking and signaling^[@R15]--[@R16]^. The dual roles of aGPCRs in promoting cell-cell/cell-matrix interactions and facilitating intracellular signaling, in addition to the importance of Gpr126 for SC myelination^[@R10]--[@R13]^, led us to hypothesize that additional aGPCRs regulate glial cell development and myelination in the CNS.

Previously published datasets indicate that *Gpr56*, an aGPCR related to Gpr126, is highly expressed during mouse CNS development in OPCs^[@R17]--[@R18]^. In addition, mutations in *GPR56* in humans cause bilateral frontoparietal polymicrogyria (BFPP)^[@R19]^, a cortical brain malformation associated with a variety of devastating neurological impairments such as epilepsy and mental retardation. Interestingly, brains of BFPP patients also exhibit reduced white matter volume by MRI^[@R20]--[@R22]^, indicative of myelin defects. Taken together, these data suggest that Gpr56 may function in oligodendrocyte development. To test this hypothesis, we utilize zebrafish and mouse model systems to explore the necessity of *Gpr56* in the CNS. We show that impaired Gpr56 function results in reduced numbers of myelinating oligodendrocytes and hypomyelination due to decreased OPC proliferation rather than failed specification of the oligodendrocyte lineage. Additionally, transient overexpression of *gpr56* in wildtype (WT) zebrafish increases numbers of pro-OLs but inhibits terminal differentiation of mature oligodendrocytes. Finally, we show that these functions are mediated by interactions with Gα~12/13~ G-proteins and RhoA signaling. Together, our studies implicate Gpr56 as an essential regulator of oligodendrocyte development and myelination.

RESULTS {#S1}
=======

*gpr56* is expressed during oligodendrocyte development {#S2}
-------------------------------------------------------

Myelin is an evolutionary innovation of the jawed vertebrate lineage^[@R23]^, and zebrafish represent one of the simplest genetically tractable organisms in which to study myelinating glial cell development. We therefore took advantage of the zebrafish model system to interrogate the necessity of Gpr56 function in oligodendrocyte development and myelination. First, we analyzed the spatiotemporal expression of *gpr56* by RT-PCR in developing zebrafish. We detected *gpr56* expression during embryogenesis and in early larval stages (2 through 5 days post-fertilization (dpf)) when OPCs are first specified and differentiate^[@R24]^ ([Fig. 1a](#F1){ref-type="fig"}). In addition, whole-mount *in situ* hybridization (WISH) revealed low levels of *gpr56* expression throughout the CNS at 1 dpf, prior to OPC specification^[@R24]^ ([Fig. 1b](#F1){ref-type="fig"}). These findings are consistent with previously published data in mammals showing that *Gpr56* is also expressed in astrocytes, and to a lesser extent, in neurons^[@R18]^. At 2 dpf, when OPCs have been specified and are actively migrating and dividing^[@R24]^, there was a dramatic increase in *gpr56* expression in the CNS ([Fig. 1c](#F1){ref-type="fig"}). Cross-sections of 2 dpf WISH embryos revealed that *gpr56* is expressed along the spinal cord midline and in a single distinct band running dorsal to ventral on either side of the midline, consistent with expression in neural precursors ([Fig. 1d](#F1){ref-type="fig"}). In contrast, *gpr56* expression was not detected by WISH in the CNS at larval stages \>3 dpf ([Supplementary Fig. 1a--b](#SD1){ref-type="supplementary-material"}), during which time oligodendrocytes undergo terminal differentiation^[@R24]--[@R25]^. We also never detected signal in sense control WISH experiments ([Supplementary Fig. 1c](#SD1){ref-type="supplementary-material"}). These findings demonstrate that *gpr56* expression during CNS development is conserved from zebrafish to mammals and suggest that levels are highest at earlier stages.

Targeted disruption of *gpr56* in zebrafish {#S3}
-------------------------------------------

Given the expression pattern of *gpr56* in the developing CNS, we sought to test the hypothesis that Gpr56 regulates oligodendrocyte development. To this end, we generated [T]{.ul}ranscription [A]{.ul}ctivator-[L]{.ul}ike [E]{.ul}ffector [N]{.ul}ucleases (TALENs)^[@R26]^ designed to cleave zebrafish *gpr56* genomic sequences between exons 8 and 9 ([Fig. 1e](#F1){ref-type="fig"}), which encode the GPS motif. We recovered two mutant alleles of *gpr56: stl13* representing a 6 bp deletion that is predicted to remove a completely conserved tryptophan residue, and *stl14* representing a 26 bp deletion ([Fig. 1f--g](#F1){ref-type="fig"}). The GPS is a cysteine-rich domain containing four cysteine residues and two tryptophan residues required for autoproteolytic cleavage^[@R27]^. Previous reports show that inhibiting autoproteolytic cleavage of GPR56 prevents receptor trafficking and therefore impairs signaling^[@R20]^. In addition, two missense mutations that disrupt the highly conserved cysteine and tryptophan residues in humans cause BFPP^[@R27]^. Together, these findings suggest that *gpr56^stl13/stl13^* mutants may generate a non-functional Gpr56 due to failed trafficking of the receptor to the plasma membrane. Therefore, we chose to primarily characterize and utilize *stl13* as a tool for understanding *gpr56* function.

Gpr56 is required for proper oligodendrocyte development {#S4}
--------------------------------------------------------

To determine whether Gpr56 is required for normal oligodendrogliogenesis, we performed marker analyses to observe oligodendrocyte development in *gpr56^stl13/stl13^* mutants. In the CNS, oligodendrocyte precursor cells (OPCs) differentiate from neural progenitors that reside within subventricular zones of the embryonic brain and spinal cord through coordinated expression of the transcription factors Olig2 and Sox10^28^. Some OPCs remain as non-myelinating OPC progenitors throughout life, while others are further specified by expression of the transcription factor *Nkx2.2*, which allows OPCs to enter the terminal differentiation pathway. Expression of *Nkx2.2* is characteristic of axon-associated pro-oligodendrocytes^[@R25]^, and mature myelinating oligodendrocytes express *Myelin basic protein* (*Mbp*), which encodes a structural component of the myelin sheath^[@R28]^. Using transgenic *sox10(−7.2):memgfp* zebrafish (a kind gift from M. Voigt, manuscript in preparation), we did not detect any difference in the number of *sox10*+ OPCs in *gpr56^stl13/13^* larvae (*N=19*) compared to controls (*N=20*) at 28 hpf, the earliest time-point at which *sox10* expression was detected ([Fig. 2a--c](#F2){ref-type="fig"}, *p\<.09*, Student's t-test). These data suggest that specification of the oligodendrocyte lineage is not impaired in *gpr56^stl13/stl13^* mutants. Consistent with this observation, general dorsal-ventral patterning (visualized by Sonic hedgehog pathway markers) was also unaffected in *gpr56^stl13/13^* mutants ([Supplementary Fig. 2](#SD1){ref-type="supplementary-material"}). Furthermore, we did not observe overt defects in the development of neurons, radial glia, or in microglia number at any stage examined in *gpr56^stl13/13^* mutants compared to controls ([Supplementary Fig. 3](#SD1){ref-type="supplementary-material"}). However, by 2.5 dpf, we detected a significant decrease (*p\<5.223×10 ^−6^*, Student's t-test) in *nkx2.2a*+ pro-oligodendrocyte (pro-OL) number in *gpr56^stl13/13^* mutants (*N=19*) by WISH relative to controls (*gpr56^+/+^* and *gpr56^stl13/+^*: *N=22*), and we observed a subsequent reduction in CNS *mbp* expression in *gpr56* mutants (*gpr56^stl13/stl13^*: *N=20/27, gpr56^stl14/stl14^*: *N=14/19*) by 4 dpf ([Fig. 2d--i](#F2){ref-type="fig"}, WT control: *N=13/13*). Although *gpr56* is maternally expressed ([Fig. 1a](#F1){ref-type="fig"}), we did not observe enhanced defects in oligodendrocyte development in *gpr56^stl13/stl13^* maternal-zygotic mutants (no WT maternal contribution) compared to *gpr56^stl13/stl13^* zygotic mutants ([Fig. 2j](#F2){ref-type="fig"}, *N=5/5*). Importantly, injection of synthetic mRNA encoding WT zebrafish (50 pg) or mouse (200 pg) *Gpr56* was sufficient to rescue the CNS *mbp* deficits in *gpr56^stl13/stl13^* mutants, confirming the specificity of the TALEN-induced mutations ([Supplementary Fig. 4](#SD1){ref-type="supplementary-material"}). Together, these results demonstrate that Gpr56 is required for the proper development of mature, myelinating oligodendrocytes.

Mutations in *gpr56* cause CNS hypomyelination {#S5}
----------------------------------------------

To further delineate how impaired Gpr56 function affects oligodendrocyte myelination, we performed transmission electron microscopy (TEM) to measure the extent and quality of myelin present in the ventral spinal cord of *gpr56* mutants (*gpr56^stl13/stl13^*: *N=5, gpr56^stl14/stl14^*: *N=4*, WT: *N=6*) during development ([Fig. 3a--k](#F3){ref-type="fig"}). We found a significant reduction (*gpr56^stl13/stl13^*, *p\<.019; gpr56^stl14/stl14^*, *p*\<.039, Student's t-test) in the percent of myelinated axons in mutant larvae compared to WT controls at 5 dpf ([Fig. 3l](#F3){ref-type="fig"}), but total axon number was unchanged (*gpr56^stl13/stl13^*, *p\<.5; gpr56^stl14/stl14^*, *p*\<.78, Student's t-test [Fig. 3m](#F3){ref-type="fig"}). We also did not observe a change in the number of myelin wraps surrounding those axons that were myelinated in *gpr56^stl13/stl13^* mutants compared to controls ([Fig. 3n--o](#F3){ref-type="fig"}; non-Mauthner: *gpr56^stl13/stl13^*: *p\<.29*, *gpr56^stk14/stl14^*: *p\<.6*; Mauthner: *gpr56^stl13/stl13^*: *p\<.25*, *gpr56^stk14/stl14^*: *p\<.76*, Student's t-test). In contrast to the hypomyelination phenotype shown in the ventral spinal cord of *gpr56* mutants at 5 dpf ([Fig. 3f--k](#F3){ref-type="fig"}), we did not observe any effect on oligodendrocyte myelination in the dorsal spinal cord at this developmental stage ([Supplementary Fig. 5](#SD1){ref-type="supplementary-material"}). By 21 dpf, however, we observed a statistically significant decrease in the percent of myelinated axons in the ventral (*p*\<.007, Student's t-test) and dorsal (*p*\<.002) spinal cord of *gpr56^stl13/stl13^* (*N=4*) mutants relative to WT siblings (*N=2*), with no change in axon number ([Supplementary Fig. 6](#SD1){ref-type="supplementary-material"}, dorsal spinal cord: *p\<.89*, ventral spinal spinal: *p\<.96*, Student's t-test). We suspect that we were unable to detect a difference in the dorsal spinal cord at larval stages because so few axons are myelinated in this region at 5 dpf. Interestingly, we also observed many oligodendrocytes with distended endoplasmic reticula in *gpr56^stl13/stl13^* mutants at 21 dpf, which was rarely seen in controls, supporting the hypothesis that the protein encoded by *gpr56^stl13/stl13^* does not traffic properly from the ER to the plasma membrane ([Supplementary Fig. 6](#SD1){ref-type="supplementary-material"}). To determine if myelination is simply delayed in *gpr56^stl13/stl13^* mutants, we analyzed myelin ultrastructure in the spinal cord of *gpr56^stl13/stl13^* animals at 6 months of age ([Supplementary Fig. 7](#SD1){ref-type="supplementary-material"}). At 6 months, we likewise found a statistically significant decrease in the percent of myelinated axons in *gpr56^stl13/stl13^* mutants (*N=4*) compared to WT controls (*N=3*) in both the ventral ([Supplementary Fig. 7g](#SD1){ref-type="supplementary-material"}, axon diameter of .2--.5 µm (*p\<.021*), .5--1 µm (*p\<.005*), and 1--2 µm (*p\<.029*), Student's t-test) and dorsal spinal cord ([Supplementary Fig. 7n](#SD1){ref-type="supplementary-material"}, axon diameter of .2−.5 µm (*p\<.003*) and .5--1 µm (*p\<.008*), Student's t-test), without any change in myelin thickness for axons that were myelinated ([Supplementary Fig. 7h,o](#SD1){ref-type="supplementary-material"}, linear regression analysis). Axon number was also unchanged in mutants compared to controls ([Supplementary Fig. 7f,m](#SD1){ref-type="supplementary-material"}, dorsal spinal cord: *p\<.11*, ventral spinal cord: *p\<.34*, Student's t-test). Collectively, our analysis demonstrates that altered Gpr56 function causes developmental CNS hypomyelination that persists in the adult spinal cord.

Gpr56 is not required for neural stem cell differentiation {#S6}
----------------------------------------------------------

One possible explanation for the observed decrease in myelinating oligodendrocyte numbers in *gpr56^stl13/stl13^* mutants could be reduced differentiation of the oligodendrocyte lineage from neural stem cells. The fact that we did not detect defects in early OPC specification ([Fig. 2a--c](#F2){ref-type="fig"}) in *gpr56^stl13/stl13^* zebrafish mutants argued against this, but to definitively test this model, we harvested neurospheres from the subventricular zone of *Gpr56*−/− knockout mice^[@R29]^ at postnatal day 3 and assessed their ability to differentiate into Tuj1+ neurons, GFAP+ astrocytes, and O4+ oligodendrocytes. Importantly, we found robust levels of Gpr56 protein in neurospheres harvested from WT and *Gpr56* +/− animals, which was absent from mutant neurospheres ([Supplementary Fig. 8](#SD1){ref-type="supplementary-material"}). We observed no differences in the ability of *Gpr56*−/− neural stem cells to differentiate into any cell type tested ([Fig. 4](#F4){ref-type="fig"}), consistent with our analysis of *gpr56^stl13/stl13^* zebrafish mutants ([Fig. 2a--c](#F2){ref-type="fig"}; [Supplementary Fig. 3](#SD1){ref-type="supplementary-material"}). Of note, neurospheres harvested from the spinal cord of *Gpr56−/−* animals showed a slightly increased potential to differentiate into neurons ([Supplementary Fig. 9](#SD1){ref-type="supplementary-material"}), highlighting the variation that exists between neural progenitor populations from different tissues^[@R30]^. Importantly, neurospheres harvested from both tissues showed no difference in their ability to differentiate into oligodendrocytes compared to controls, supporting the hypothesis that Gpr56 is not required for specification and differentiation of the oligodendrocyte lineage.

Gpr56 regulates OPC proliferation {#S7}
---------------------------------

Because OPC specification is unaffected in *gpr56^stl13/stl13^* zebrafish mutants, and loss of *Gpr56* does not affect the ability of neural precursors to differentiate into oligodendrocytes, reduced pro-OL numbers in *gpr56^stl13/stl13^* mutants could result from increased death and/or decreased proliferation of OPCs. To distinguish between these possibilities, we performed time-lapse imaging of *gpr56^stl13/stl13^* mutants and controls using transgenic *sox10(−7.2):mRFP*^[@R24]^ zebrafish to visualize OPC behavior and development *in vivo* ([Supplementary Movies 1--2](#SD1){ref-type="supplementary-material"}). Embryos were imaged from 30 hpf to 46 hpf, allowing us to monitor the transition of many OPCs into pro-OLs. At 30 hpf, we found a statistically significant increase in the number of axons associated with pro-OLs in *gpr56^stl13/stl13^* mutants (*N=7*) compared to controls (*N=7, p\<.04*, Student's t-test). Over time, however, the number of pro-OL associated axons in control embryos increased at a higher rate than in *gpr56^stl13/stl13^* mutants. This increase resulted in a statistically significant reduction in pro-OL associated axons in *gpr56^stl13/stl13^* mutants compared to controls by 46 hpf ([Fig. 5a--c](#F5){ref-type="fig"}, *p\<.004*, Student's t-test), consistent with our marker analysis ([Fig. 2d--f](#F2){ref-type="fig"}). These findings suggest that in *gpr56^stl13/stl13^* mutants, OPCs are born and prematurely form associations with axons, but that they do not proliferate sufficiently to account for the total number of axons that need to be myelinated. In accordance with this hypothesis, we also observed additional myelinated axons in the ventral spinal cord of *gpr56^stl13/stl13^* mutants (*N=3*) compared to controls (WT: *N=3, gpr56^stl13/+−^*: *N=3*) by TEM at 3 dpf ([Fig. 5d--g](#F5){ref-type="fig"}, *p\<.048*, Student's t-test), indicative of precocious myelination. In addition, we observed a statistically significant reduction in the number of proliferating OPCs (*sox10+;* pH3+) in *gpr56^stl13/stl13^* mutants compared to controls at 32 hpf, when most OPCs have not yet entered the differentiation program^[@R24]--[@R25]^ ([Fig. 5h--j](#F5){ref-type="fig"}, *p\<.0004*, Student's t-test). Importantly, we did not observe any signs of cell death via time-lapse imaging, and there was no increase in the number of cell corpses assessed by acridine orange staining at 32 hpf, 2 dpf, or 3 dpf in *gpr56^stl13/stl13^* mutants compared to controls ([Fig. 5k--m](#F5){ref-type="fig"}). Thus, changes in pro-OL number can only be attributed to changes in OPC proliferation, and not cell death. Together, these data support a model in which Gpr56 promotes OPC proliferation at the expense of differentiation such that when Gpr56 function is impaired, insufficient OPC proliferation results in fewer pro-OLs and mature oligodendrocytes, which leads to hypomyelination.

*gpr56* OE increases OPC number but inhibits myelination {#S8}
--------------------------------------------------------

Impaired Gpr56 function results in reduced numbers of myelinating oligodendrocytes and myelin due to decreased OPC proliferation ([Fig. 2](#F2){ref-type="fig"}--[3](#F3){ref-type="fig"}, [5](#F5){ref-type="fig"}, [Supplementary Fig. 6--7](#SD1){ref-type="supplementary-material"}). Transient overexpression (OE) of WT *Gpr56* synthetic mRNA rescues CNS *mbp* expression ([Supplementary Fig. 4](#SD1){ref-type="supplementary-material"}) by suppressing the OPC proliferation defect observed in *gpr56^stl13/stl13^* mutants ([Supplementary Fig. 10](#SD1){ref-type="supplementary-material"}). Interestingly, we also observed enhanced *mbp* expression in a large fraction of *gpr56* injected embryos ([Supplementary Fig. 4d, e](#SD1){ref-type="supplementary-material"}). We therefore hypothesized that transient OE of *gpr56* in WT embryos would cause hypermyelination by increasing oligodendrocyte number. Analysis of *nkx2.2a* expression revealed a statistically significant increase in the number of *nkx2.2a*+ pro-OLs in the anterior (*p\<8.7×10^−7^*, Student's t-test) and posterior (*p\<.01*, Student's t-test) spinal cord ([Fig. 6a--f](#F6){ref-type="fig"}) of embryos injected with 50 pg of WT *gpr56* synthetic mRNA (anterior: *N=25*, posterior: *N=29*) relative to control injected embryos (anterior: *N=26*, posterior: *N=31*). In addition, we noted an increase in CNS *mbp* expression in *gpr56*-OE embryos relative to phenol-red injected controls by WISH ([Fig. 6g--j](#F6){ref-type="fig"}, *N=19/34*) at 2.5 dpf. Consistent with these findings, we observed an increase in the numbers of oligodendrocyte lineage nuclei in the spinal cord of *gpr56*-OE embryos relative to phenol-red injected controls by TEM at 2.5 dpf and 5 dpf ([Fig. 6l--q](#F6){ref-type="fig"}; *p\<.037* at 2.5 dpf(OE: *N=4*, control-injected: *N=4*); *p\<.15* at 5 dpf(OE: *N=5*, control-injected: *N=4*), Student's t-test). We distinguished oligodendrocyte and OPC nuclei from neuronal nuclei by their distinctive heterochromatin conformations. OPC and oligodendrocyte heterochromatin is heavily condensed and localized along the perimeter of the nucleus for OPCs or in patches throughout for post-mitotic, terminally differentiated oligodendrocytes. In contrast, neuronal heterochromatin is organized uniformly throughout the nucleus, often with a single dense nucleolus^[@R31]--[@R33]^. At 2.5 dpf, generally only the large Mauthner axons are myelinated in WT zebrafish^[@R34]^, but in some OE embryos, additional myelinated axons were observed compared to controls at this time point by TEM (*N*=2/4 in the ventral spinal cord and *N=1/4* in the dorsal spinal cord, [Supplementary Fig. 11](#SD1){ref-type="supplementary-material"}), although the difference was not significant. Taken alone, these data suggest that OE of *gpr56* may induce hypermyelination; however, we observed hypomyelination in *gpr56*- OE embryos relative to controls at 5 dpf by TEM ([Fig. 6r--x](#F6){ref-type="fig"}). These findings indicate that OE of *gpr56* increases *mbp* expression by increasing pro-OL number but that this *mbp* expression is not equivalent to true myelination, and OE of *gpr56* inhibits terminal differentiation and myelination. Collectively, these data support the hypothesis that Gpr56 is both a positive regulator of OPC proliferation and a negative regulator of oligodendrocyte differentiation.

Gα~12/13~ and RhoA manipulations alter *gpr56* mutant phenotypes {#S9}
----------------------------------------------------------------

Previous *in vitro* studies show that Gpr56 couples to Gα~12/13~ and activates RhoA to control migration of mammalian neural precursor cells^[@R35]--[@R36]^. We likewise found that RhoA activity levels are high in control neurospheres when Gpr56 is abundant ([Supplementary Figure 12](#SD1){ref-type="supplementary-material"}). In OPCs, RhoA is highly expressed, but is later downregulated to facilitate terminal differentiation of oligodendrocytes in mammals^[@R37]^, which is consistent with the spatiotemporal expression profile we observe for *gpr56* in zebrafish ([Fig. 1a--d](#F1){ref-type="fig"}). Taken together, these data suggest that Gpr56 may couple to Gα~12/13~ and activate RhoA during oligodendrocyte development. To test these hypotheses, we first used established antisense morpholino oligonucleotides that transiently impair Gα~12/13~ function in *gpr56^stl13/stl13^* mutants through translational inhibition of three previously identified Gα~12/13~ transcripts ("3MO"; *gna12*, *gna13a*, and *gna13b*)^[@R38]^. We then analyzed *mbp* expression by WISH to assess oligodendrocyte development, and embryos were scored from 0--3 based on the strength of their expression: 0 = nearly absent, 1 = strongly reduced, 2 = reduced, 3 = wildtype ([Fig. 7a--d](#F7){ref-type="fig"}). We treated embryos with low doses of 3MO (1 ng each) such that WT, 3MO-injected embryos showed no phenotype ([Fig. 7e--f](#F7){ref-type="fig"}). In contrast, sub-threshold doses of 3MO caused significant hypomyelination in *gpr56^stl13/+^* heterozygotes and severe hypomyelination in homozygous mutants, resulting in a dramatic shift in the distribution of their phenotypic classes and a significant reduction in their CNS *mbp* score ([Fig. 7e--f](#F7){ref-type="fig"}, control WT (*N=23*) versus control heterozygote (*N=56*): *p\<0.077*; control WT (*N=23*) versus control mutant (*N=32*): *p\<.0003*; 3MO-injected WT (*N=10*) versus 3MO-injected heterozygote (*N=36*): *p\< 1.33×10^−5^*; 3MO-injected WT (*N=10*) versus 3MO-injected mutant (*N=15*): *p\< 2.59×10^−6^*, Student's t-test). Because inhibition of Gα~12/13~ function preferentially affects oligodendrocyte development in *gpr56^stl13/+^* heterozygotes and mutants compared to WT controls, our findings suggest a genetic interaction and thus support the hypothesis that Gpr56 promotes oligodendrocyte development via interactions with Gα~12/13~.

Rho is the main downstream effector of Gα~12/13~^[@R39]^, and previous studies *in vitro* implicate RhoA signaling downstream of Gpr56^[@R35]--[@R36]^. We therefore hypothesized that Gpr56 couples to Gα~12/13~ and signals through RhoA to promote oligodendrocyte development. Consistent with this model, transient OE of 10 pg of a constitutively active form of *rhoa* (*rhoV14*)^[@R38]^ suppressed *gpr56^stl13/stl13^* mutant phenotypes, including the OPC proliferation defect ([Supplementary Fig. 10](#SD1){ref-type="supplementary-material"}) and CNS *mbp* score ([Fig. 7i--j](#F7){ref-type="fig"}, control WT (*N=22*) versus control mutant (*N=27*): *p\<.0009*; OE WT (*N=16*) versus OE mutant (*N=17*): *p\<.343*, Student's t-test). OE of *rhoa* also caused a dramatic shift in the distribution of phenotypic classes in *gpr56^stl13/stl13^* mutants such that the majority (76%) of *gpr56^stl13/stl13^* larvae expressed WT levels of *mbp* ([Fig. 7i](#F7){ref-type="fig"}, *N=13/17*). Importantly, all embryos analyzed for these studies were morphologically normal, and thus changes in *mbp* expression could not be attributed to changes in overall heath in treated animals compared to controls ([Fig. 7g--h](#F7){ref-type="fig"}, k-l). Taken together, these experiments demonstrate that Gpr56 interacts with Gα~12/13~ and signals through RhoA to promote oligodendrocyte development and subsequent myelination.

DISCUSSION {#S10}
==========

The timing of the transition from OPC proliferation to terminal differentiation is tightly regulated^[@R40]--[@R42]^. In the CNS, interactions between receptors on the OPC cell surface and axon-bound or axon-secreted molecules ensure that sufficient numbers of OPCs are generated to accommodate the numbers of axons that need to be myelinated. Availability of the axon-derived mitogen PDGF-A, which interacts with PDGFRα on the OPC plasma membrane, is a major determinant of the extent of OPC proliferation. Moreover, numerous mechanisms converge to ensure the timing and execution of terminal differentiation, including downregulation of *Pdgfrα* by Nkx2.2 in OPCs, cell-cycle exit, and vast morphological changes^[@R37],\ [@R42]--[@R45]^. Failed differentiation of resident OPC pools in response to demyelination is a major contributor to the degenerative nature of demyelinating diseases such as multiple sclerosis^[@R46]^; thus, identification of signaling molecules that regulate OPC behavior and differentiation could provide new avenues for therapeutics.

In this study, using zebrafish and mouse models, we identified Gpr56 as a new regulator of OPC proliferation and oligodendrocyte myelination. Like PDGFRα,*Gpr56* expression is restricted to early stages of oligodendrocyte development and is downregulated prior to terminal differentiation^[@R18],\ [@R42]^, suggesting that Gpr56 may negatively regulate terminal differentiation and/or positively regulate OPC behavior/proliferation. Gpr17, another GPCR that is essential for oligodendrocyte development, is also expressed in OPCs and is downregulated in mature oligodendrocytes, and Gpr17 has been shown to directly inhibit terminal differentiation. In the absence of *Gpr17*, OPCs prematurely differentiate and form myelin, though myelination eventually proceeds to WT levels in *Gpr17−/−* mice^[@R47]^. We found that *gpr56^stl13/stl13^* mutant OPCs likewise formed associations with axons and myelinated prematurely, indicative of precocious differentiation due to relieved inhibition on terminal differentiation We found that OPCs are specified normally in *gpr56^stl13/stl13^* mutants but are less proliferative, resulting in reduced numbers of myelinating oligodendrocytes and consequently, hypomyelination. In addition, transient OE of *gpr56* in WT embryos caused increased numbers of pro-OLs and increased *mbp* expression in *gpr56* OE embryos at 2.5 dpf,. However, the apparent increase in *mbp* expression is likely the result of greater numbers of pro-OLs, as myelination was inhibited in the OE embryos at 5 dpf as assessed by TEM. We also observed many immature oligodendrocyte cell bodies with no axonal contacts in the center of the spinal cord of the overexpression embryos at this time-point. These findings indicate that that prolonged OE of *gpr56* inhibits OPC differentiation and myelination. Together, these findings support the hypothesis that Gpr56 is both a positive regulator of OPC proliferation and an inhibitor of oligodendrocyte terminal differentiation.

Though we observed striking defects in oligodendrocyte development and myelination when Gpr56 function is perturbed, we did not observe any defects in the development of neurons, radial glia, or in microglia number in *gpr56^stl13/stl13^* mutants at any time point analyzed. These data suggest that the observed defects in oligodendrocyte development are a cell-autonomous effect, although conditional mouse mutant studies could be leveraged to definitively address the question of cellular autonomy. Together, these data demonstrate that Gpr56 is a positive regulator of OPC proliferation and a negative regulator of OPC differentiation.

Previous *in vitro* studies place Gα~12/13~ and RhoA signaling downstream of Gpr56^[@R35]--[@R36]^. RhoA is the major downstream effector of Gα~12/13~ and its expression is likewise restricted to early stages of oligodendrocyte development^[@R37],[@R39]^. Inactivation of RhoA via Fyn is required for OPC morphological differentiation into pro-OLs, and sustained overexpression of RhoA inhibits process extension and differentiation of oligodendrocytes^[@R37]^. Reduction of Gα~12/13~ function in *gpr56^stl13/stl13^* zebrafish mutants and heterozygotes causes enhanced loss of CNS *mbp* expression. In addition, transient OE of constitutively active RhoA prior to terminal differentiation suppressed *gpr56^stl13/stl13^* defects. In sum, these data support a model in which Gpr56 function in OPCs is mediated via interactions with Gα~12/13~ and RhoA signaling.

RhoA has not been shown to directly promote OPC proliferation, though our findings do not preclude this possibility. We therefore propose a model in which Gpr56 interacts with Gα~12/13~ and activates RhoA to prevent OPC differentiation, which facilitates continued OPC proliferation promoted by axon-glia interactions such as those mediated by PDGFRα and PDGF-A^[@R42]--[@R44]^. When Gpr56 function is perturbed, RhoA activation is therefore reduced, relieving RhoA inhibition of terminal differentiation and causing premature OPC differentiation that manifests in a reduced proliferation phenotype ([Fig. 8](#F8){ref-type="fig"}). In this model, the OPCs that prematurely undergo terminal differentiation should myelinate normally. Accordingly, we detected an increase in axons associated with pro-OLs at 30 hpf and increased myelination at 3 dpf, consistent with precocious differentiation. Furthermore, we observed no myelin abnormalities or reduced myelin thickness in those axons that are myelinated in *gpr56^stl13/stl13^* mutants. In sum, these data support the model that Gpr56 positively regulates OPC proliferation via RhoA activation and inhibition of terminal differentiation.

At present, multiple ligands of Gpr56 have been identified in other cell types. In cancer studies, Gpr56 has been shown to inhibit melanoma cell growth via interactions with tissue transglutaminase (TG2)^[@R48]^. In the developing brain, collagen type III, alpha-1secreted by meningeal fibroblasts interacts with neuron-bound Gpr56 to facilitate proper neuronal migration^[@R36]^. Impaired differentiation of OPC progenitors is a major cause of failed remyelination in the CNS of patients suffering from demyelinating diseases such as multiple sclerosis^[@R46]^. Therefore, a better understanding of Gpr56 activation and signaling is crucial as targeted inhibition of this receptor could be used to promote OPC differentiation and remyelination after injury and disease-induced demyelination. Future studies are required to identify the endogenous ligand(s) and small molecules that modulate Gpr56 signaling in OPCs.

METHODS {#S11}
=======

Zebrafish stocks and rearing conditions {#S12}
---------------------------------------

Zebrafish (*Danio rerio*) were maintained in the Washington University Zebrafish Consortium facility (<http://zebrafish.wustl.edu/husbandry.htm>). All experiments were performed in compliance with Washington University's institutional animal protocols. Embryos were collected from pair-wise or harem matings and reared at 28.5° C in egg water (5 mM NaCl, 0.17 mM KCl, 0.33 mM CaCl~2~, 0.33 mM MgSO~4~). Embryos were staged in hours post-fertilization (hpf) or days post-fertilization (dpf) using morpholical markers ^[@R49]^. To prevent pigmentation in embryos \> 1 dpf, egg water was supplemented with phenylthiourea to .003%. The following lines of zebrafish were used for these studies: both alleles of *gpr56* (*stl13, stl14*) were generated in a WT (AB\*) background. For marker analysis, we used the following transgenic lines: *tg*(*gfap:GFP*)^[@R50]^, *tg(sox10(−7.2):mRFP)*^[@R24]^, *tg(olig2:dsred)*^[@R51]^, *tg(HuC:kaede)*^[@R52]^, and *tg(sox10(−7.2):memgfp*) was a generous gift from Mark Voigt (St. Louis University).

Genotyping {#S13}
----------

To genotype individual larvae for phenotypic analyses, we used the following primers to amplify a 182 bp fragment of *gpr56* from genomic DNA: 5'- CATGGGATACAAAACAAGGT −3' and 5'- AGTGGCATTCTGTCTGTTCT - 3'. For *stl14*, PCR products were run out on a 3% agarose gel and the smaller fragment (158 bp) is the mutant allele. For *stl13*, we performed restriction digest analysis using Hpy166II, which cleaves WT into a 61 bp and a 121 bp fragment, but is unable to cut mutant (176 bp).

TALEN generation and microinjection {#S14}
-----------------------------------

TALEN constructs were assembled by the Hope Center for Neurological Disorders at Washington University using the Golden Gate TALEN assembly protocol ^[@R53]^. The repeat variable diresidue sequences for the left and right TALENs were as follows: [Left]{.ul}: NN NG NG NG HD NG HD HD HD NG NI NN NI HD NI NI NG and [Right]{.ul}: NI NI HD NG NN NG NI NG HD NN HD NI NN HD HD NI NG HD NI NG. Synthetic TALEN mRNA was then transcribed using the mMESSAGE mMACHINE® SP6 ULTRA kit (Ambion), and RNA from each arm was combined and injected into 1-cell stage WT embryos (AB) at 100 pg quantities. To recover germ-line transmitted mutations, injected founders (F0s) were raised to adulthood, outcrossed to WT AB partners, and genomic DNA was extracted from individual F1 embryos for PCR amplification and restriction digest analysis of the targeted region. Genomic DNA from F1 embryos that showed disruption of the target site was then cloned using the TOPO® TA Cloning® kit (Invitrogen) and sequenced using Sanger sequencing.

Mice {#S15}
----

All mouse (*Mus musculus*) experiments were performed in compliance with Washington University\'s institutional animal protocols. The *Gpr56* knock-out mice were obtained from the Mutant Mouse Regional Resource Centers (MMRRC), were maintained on a C57BL/6 background, and genotyped as described previously^[@R29]^. P3 animals of presumed mixed gender were used for all neurosphere experiments, although pups were not genotyped for gender.

RT-PCR {#S16}
------

Standard RT-PCR was performed on cDNAs derived from embryos at the 2-cell stage (Maternal), 8 hpf, 24 hpf, 48 hpf, 72 hpf, and 5 dpf. Analysis was performed 3 separate times with similar results. For all stages, cDNA was reverse-transcribed from RNA extracted from pools of 30 embryos with the SuperScript First-Strand Synthesis system for RT-PCR (Invitrogen) using Superscript II reverse transcriptase (RT) and oligo(dT) primers, and genomic DNA was controlled for by omitting RT from reactions using the same RNA. To amplify *gpr56*, we used primers that amplify a 602 bp fragment from exons 3--7: 5'- TCATCCAGAAGAGCTGATTT - 3' and 5'- GAAATTTCAGCCAATGAGAG - 3'. *gapdh* was amplified as a control to produce a 117 bp product: 5' -- TGACCCATTCATTGACCTTG - 3' and 5'- GCATGACCATCAATGACCAG - 3'.

Cloning {#S17}
-------

Full length, *gpr56* cDNA was amplified from cDNA derived from 5 dpf embryos and cloned into pCS2+ using the following primer set: 5 - GATCTA[CTCGAG]{.ul}TTGGTAGAAAGTGGACTTCG - 3 (XhoI site underlined) and 5 - AGGATA[TCTAGA]{.ul}TTCCCTCACAACTTCACACT - 3 (XbaI site underlined). Both vector and insert were digested with XhoI and XbaI and ligated together using standard T4 ligase (NEB), and the final vector (pCS2+\_ zf\_*gpr56*) was sequenced for verification.

*In situ* hybridization {#S18}
-----------------------

Whole-mount *in situ* hybridizations were performed using standard protocols^[@R54]^. Briefly, embryos were fixed at the desired age with 4% paraformaldehyde for 2 hours and room temperature of 4° C overnight, and then dehydrated in 100% Methanol overnight. Following dehydration, embryos were washed in .2% PBS-Tween (PBSTw), permeabilized in proteinase K (20mg/ul diluted 1:1000 in .2% PBSTw), and incubated with the appropriate Digoxygenin-labeled riboprobe overnight at 65° C in hybridization buffer (50% formamide). Following probe-treatment, embryos were washed to remove formamide, blocked in 2% blocking medium supplemented with 10% normal sheep serum and .2% Triton, and incubated in primary antibody (Anti-Dig, Fab fragments (1:2000), Roche) overnight in block. Following primary antibody treatment, embryos were washed in Maleic Acid Buffer with .2% triton, and developed by alkaline phosphatase treatment. After complete, embryos were post-fixed in 4% paraformaldehyde and stored long-term in 70% glycerol.To synthesize *gpr56* riboprobes, a 509 bp region spanning exons 11--13 was PCR amplified from a partially sequenced cDNA clone (Clone ID 7070653, Open Biosystems) using the following primer pair: 5\' - ATTTCTGCTGTGCTTGTTCT - 3' and 5' - CATGTGGTTCCATACAGACA - 3\'. The PCR product was cloned into pCR II using the pCR II- TOPO® TA Cloning® kit (Invitrogen) and sequenced. This construct was linearized by NotI and transcribed with SP6 for sense and linearized with BamHI and transcribed with T7 for antisense. All other riboprobes: *mbp*^[@R55]^, *nkx2.2a*^[@R56]^, *apoeb*^[@R57]^, *shh*^[@R58]^, *ptc1*^[@R59]^ and *ptc2*^[@R60]^ were described previously. Embryos stained with *nkx2.2a* were mounted in glycerol and *nkx2.2a* positive cells were counted manually in all focal planes of the spinal cord from segments 5--7 or 15--30. *apoeb* positive microglia were counted as previously described^[@R57]^. All quantifications were performed blinded, and genotypes were obtained following quantification.

Transmission electron microscopy {#S19}
--------------------------------

For zebrafish larvae and 21 dpf juveniles, transmission electron microscopy (TEM) was performed using a PELCO BioWave® Pro with SteadyTemp™ Digital Plus water-recirculating system to ensure sufficient infiltration of the embryos^[@R61]^. Embryos were microwaved for all steps prior to EPON treatment. Briefly, embryos were fixed in Karnovsky's fix (4% paraformaldehyde, 2% glutaraldehyde, .1M sodium cacodylate) and left overnight at 4° C. After fixation, embryos were post-fixed in 2% osmium tetroxide in .1M sodium cacodylate and .1M imidazole, washed, and treated with saturated uranyl acetate. Embryos were then dehydrated using increasing concentrations of ethanol followed by 100% acetone, and then infiltrated overnight in an acetone-EPON mixture. Embryos were then transferred to 100% EPON and embedded in molds for baking overnight at 65° C. We always examined fish of a given stage at approximately the same body segment level to control for variability along the anterior/posterior axis. For preparation of spinal cords from 6 months old adults, we anesthetized animals in an ice-water bath and then severed the hindbrain before dissecting a portion of the anterior spinal cord, and fixation of adult-tissue occurred as described previously^[@R10]^. In brief, adult tissues were fixed in Karnovsky's fix overnight, post-fixed in 2% osmium tetroxide in .1M sodium cacodylate, washed, and dehydrated in increasing concentrations of ethanol followed by 100% propylene oxide. The tissues were then submerged in a 2:1 mixture of propolyene oxide:EPON for 1 hour, followed by a 1:1 mixture overnight. The following day, the tissues were transferred to 100% EPON prior to embedding and baking at 65° C. Thin sections (70 nm) were mounted on mesh (5 dpf and 6 month samples) or slot (21 dpf samples) grids and stained with 8% uranyl acetate and Sato's lead stain. Sections were then viewed on a Jeol (JEM-1400) electron microscope and images were collected with an AMT V601 digital camera. All images were processed and analyzed using Image J software. At 3 dpf and 5 dpf, quantifications were performed on a stereotyped, 14 µm^2^ region of the dorsal or ventral spinal cord containing approximately 400 and 250 axons, respectively (see [Fig. 3b](#F3){ref-type="fig"}). At 21 dpf, quantifications were performed on three, 20 µm^2^ sections of the ventral spinal cord and two, 20 µm^2^ sections of the dorsal spinal cord containing of a minimum of 100 and 300 axons, respectively. Quantifications were performed on stereotyped positions of the spinal cord (see [Fig. 3b](#F3){ref-type="fig"}). At 6 months, quantifications were performed on a stereotyped 17 µm^2^ region of the dorsal and ventral spinal cord ([Supplementary Fig. 7a](#SD1){ref-type="supplementary-material"}). G-ratios were calculated using Adobe Photoshop and Image J software for approximately 50 axons per animal by taking the ratio of the axon diameter to the diameter of the whole myelinated fiber. At 3 dpf, *N=3* for WT and *gpr56^stl13/+^*, *N=4* for *gpr56^stl13/stl13^*. For quantification of *gpr56* mutants and controls at 5 dpf, *N= 6* for WT controls, *N=5* for *gpr56^stl13/stl13^* mutants, and *N=4* for *gpr56^stl14/stl14^* mutants. At 21 dpf, *N=2* for WT controls and *N=4* for *gpr56^stl13/stl13^* mutants. At 6 months, *N=3* for WT controls, and *N=4* for *gpr56^stl13/stl13^* mutants.

For quantification of *gpr56* injected versus control injected embryos at 2.5 dpf and 5 dpf, we manually counted the number of wraps around Mauthner axons imaged at 10,000X. At 2.5 dpf, we quantified all neuronal/oligodendrocyte-lineage cell bodies in the dorsal half of the spinal cord (located above half the height of the whole spinal cord at 1200X). *N=4* for each treatment. At 5 dpf (*N=4* for control-injected embryos, *N=5* for *gpr56* injected embryos), we quantified oligodendrocyte-lineage cell bodies within a stereotyped 30 µm^2^ region in the center of the spinal cord. Additional calculations were performed as described above. All quantifications were performed blinded to genotype and treatment.

Culture and generation of neurospheres {#S20}
--------------------------------------

For generation of neurospheres for IHC analysis, spinal cords (SC) and subventricular zones (SVZ) were dissected from postnatal (P) day 3 mice (*Gpr56+/+*: *N=3*; *Gpr56+/*-: *N=4*; *Gpr56−/−*: *N=5*) to generate NPCs as previously reported^[@R62]^. Briefly, SC and SVZ were removed from P3 mice and processed to obtain single-cell suspension of neural progenitors (neurospheres). Dissected SC and SVZ were digested with trypsin digest buffer containing 0.2% BSA (Sigma), 0.5 mg/ml DNase I (Sigma), and 10% trypsin-EDTA stock (BioWhittaker) in HBSS at 37° C for 15 min in a volume of 0.7 ml per litter. Equal volumes of 10% FBS medium containing 10% FBS (Life Technologies) and low glucose DMEM (Sigma) were added, and SC and SVZ were triturated with fire-polished Pasteur pipettes. Pelleted cells were washed with dissociation medium containing 15 mM HEPES (Sigma), 0.5% glucose in HBSS. Cells were finally resuspended in NSC medium containing a 5:3 mixture of DMEM low glucose:Neurobasal medium (Life Technologies), 0.5 mM 2-mercaptoethanol, 2 mM L-glutamine, 5 IU of penicillin, and 5 µg/ml streptomycin (BioWhittaker) supplemented with 1% N2 supplement (Life Technologies), 2% B27 supplement (Life Technologies), 20 ng/ml epidermal growth factor (EGF) (Sigma), and 20 ng/ml basic fibroblast growth factor (FGF) (R & D Systems). Cells were allowed to grow in culture for 6 days. For generation of neurospheres for western blotting analysis, subventricular zones (SVZs) were dissected from P3 mice (*Gpr56+/+*: *N=4*; *Gpr56+/*-: *N=4*; *Gpr56−/−*: *N=3*) and cultured as described above.

Neurosphere immunocytochemistry {#S21}
-------------------------------

Immunocytochemistry was performed on trypsinized NPCs grown in 50 µg/mL poly-D-lysine-coated and 10 µg/mL fibronectin-coated 24-well plates containing defined medium \[(5:3 mixture of DMEM low glucose (Life Technologies): neurobasal medium (Life Technologies), 0.5 mM 2-mercaptoethanol, 2mM L-glutamine, 5 IU of penicillin, and 5 µg/ml streptomycin (life technologies) supplemented with 1% N2 supplement (Life Technologies) and 2% B27 supplement (Life Technologies) without growth factors. After 5 days in culture, cells were fixed and stained with primary antibodies (Nestin: ab6142 (Abcam), GFAP: G9269 (Sigma-Aldrich), Tuj1: MMS-435P (Covance), and O4: MAB345 (Millipore)) at 4°C overnight. For fluorescence detection, Alexa Fluor-tagged secondary antibodies (Molecular Probes) were used and cells were counterstained with DAPI. Images were acquired using Metamorph software on a Nikon Eclipse TE300 microscope equipped with an optical camera (Optronics). Investigators were blinded to mouse genotypes and percentages of positive cells were calculated using the total number of cells in each image (DAPI nuclear stain). Data were analyzed with Prism 5 software (GraphPad Software) using a two-way ANOVA test as all data met the common assumptions (normally distributed, equal variances, independent samples) required for this test.

Neurosphere western blotting {#S22}
----------------------------

Western blots were performed as previously described^[@R62]^. Images of full western blots can be seen in [Supplementary Fig. 8 and 12](#SD1){ref-type="supplementary-material"}. Briefly, neurospheres were lysed in MAPK lysis buffer (20 mM Tris \[pH 7.0\], 10 mM EGTA, 400 mM B-glycerophosphate, 1% NP-40, 2.5 mM MgCl~2~, and 2 mM sodium orthovanadate with protease inhibitors (leupeptin, aprotinin, and phenylmethylsulfonyl fluoride). Proteins were separated by SDS-polyacrylamide gel electrophoresis (SDS-PAGE) and transferred to polyvinylidene difluoride membranes (Millipore, Billerica, MA) prior to detection with phospho-specific antibodies. Antibodies that detect the total expression of the corresponding signaling intermediate (Gpr56-H11 (1:1000)^[@R63]^; RhoA (1:1000): \#2117, Cell Signaling) as well as α-tubulin ((1:30,000), T745, Sigma) were used as controls for equal protein loading and quantitation. Active RhoA (RhoA-GTP) was determined by PAK1-PBD affinity chromatography ((1:200), M17--294, Millipore) according to the manufacturer's recommendations. Appropriate HRP-conjugated secondary antibodies (anti-rabbit (1:5000): 7074 and anti-mouse (1:5000): 7076, Cell Signaling) were used for detection by enhanced chemiluminescence (New England Biolabs).

Time-lapse imaging {#S23}
------------------

Embryos were mounted in 1% low melting agarose with tricaine to prevent movement and .003% phenylthiourea to prevent pigmentation. Embryos were oriented laterally and all images were taken of spinal cord regions spanning segments 5--7 using a 40x, dry objective. Time-lapse images were taken from *gpr56^stl13/stl13^* mutants (*N=7*) and *gpr56^stl13/+^* controls (*N=6*) expressing *tg(sox10:mRFP*)^[@R23]^ from 30 hpf to 46 hpf using a Quorum spinning disc confocal microscope on a heated stage, recorded using Metamorph software, and analyzed using Image J. All analyses were performed blinded to genotype.

Zebrafish immunohistochemistry and fluorescence imaging {#S24}
-------------------------------------------------------

For imaging of transgenes in fixed embryos, embryos were fixed in fresh, 4% paraformaldehyde supplemented with 0.1 M pipes, 1.0 mM MgSO~4~, and 2 mM EGTA in 1x PBS to preserve fluorescence^[@R64]^. For phospho-H3 antibody stains (06570MI, Millipore), embryos were fixed in 4% paraformaldehyde in 1X PBS overnight (4°C), washed in .3% PBS/Triton and then blocked for 2 hours in .3% PBS/Triton plus 10% normal goat serum and 4% BSA. Embryos were then incubated overnight at 4° C in primary diluted 1:3000 in blocking solution. For secondary staining, embryos were incubated in Alexa Flour® goat anti-rabbit 488 IgG (Life Technologies) diluted 1:2000 in .3% PBS/Triton plus 2% normal goat serum for 3 hours at room-temperature. Finally, embryos were washed and mounted in vectashield® (Vector Labs) for imaging. All quantifications were performed blinded, and genotypes were obtained following quantification.

Morpholino and synthetic mRNA injections {#S25}
----------------------------------------

The morpholinos targeting *gna12*, *gna13a*, and *gna13b* are previously published^[@R38]^ and were a kind gift from Fang Lin (University of Iowa). Morpholinos were combined and diluted in sterile water supplemented 1:10 with phenol-red dye, and then injected at a final concentration of 1 ng each in a total volume of 1 nl. To control for adverse side-effects from the injection process, we also injected control siblings with an equal volume of phenol-red diluted 1:10 in water. Contstitutively active Rho (*rhov14*) was kindly provided by Lila Solnica-Krezel and was transcribed and injected as described previously^[@R38]^. The full-length mouse *Gpr56* cDNA clone was obtained from Open Biosystems (Clone ID: 3709247), linearized with NotI, transcribed using the mMESSAGE mMACHINE® SP6 ULTRA kit (Ambion), and injected at a final concentration of 200 pg in 2 nl. For transcription of pCS2+\_ zf\_*gpr56*, the plasmid was linearized with NotI and also transcribed using the mMESSAGE mMACHINE® SP6 ULTRA kit (Ambion) before injection of a total concentration of 50 pg in 3 nl.

Statistical Analyses {#S26}
--------------------

All data is presented as the mean + or ± SD. To represent significance: \*, p \< .05; \*\*, p\< .01; \*\*\*, p\<.001. A minimum of two technical replicates were performed for each described experiment. Although we did not perform statistical tests to predetermine sample size, our samples sizes are similar to previously published studies. For cell-count, molecular marker, and time-lapse imaging analyses in zebrafish, a minimum of six animals per genotype were used for each described marker, which is in line with previously published works^[@R10],[@R55],[@R57]^. Similarly, for TEM analyses, a minimum of two WT and four mutant animals were analyzed at each developmental stage as previously described^[@R10],[@R34]^. For neurosphere studies, we used at least three animals per genotype, and for IHC experiments, cell counts were taken from three nonadjacent sections of each well in triplicate^[@R62]^. Finally, for injection studies, a minimum of ten animals were analyzed per genotype and treatment group, similar to previously published studies^[@R10],[@R55]^. Unless otherwise noted, statistical analyses were performed using an unpaired Student's t-test with 2 tails, unequal variance. With few exceptions, all data sets analyzed by a Student's t-test met the appropriate assumptions, including normality. All datasets with a skewness and kurtosis with an absolute value of ≤ 1 were considered approximately normal. The datasets that did not follow a normal distribution were represented by the following graphs: [Fig. 3o](#F3){ref-type="fig"}, [Fig. 7j](#F7){ref-type="fig"}, and [Supplementary Fig. 3i](#SD1){ref-type="supplementary-material"}. These datasets showed low variability, causing a kurtosis value of \>1. Because the mean and standard deviation values were nearly identical between both control and experimental groups for these experiments, and we found no significant difference between these groups using the student's t-test, we did not feel that the test was inappropriate for these analyses.
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![*gpr56* expression and mutant generation in zebrafish\
(**a**) Representative image of *gpr56* expression assessed by RT-PCR from fertilization through larval development (three technical replicates). From left to right: Mat (maternal expression), 8h (8 hours post-fertilization), 1d (days post-fertilization) to 5d, RT (−) control, and H~2~0 control..(**b-c**) Whole-mount *in situ* hybridization (WISH) of zebrafish larvae at (**b**) 1 and (**c**) 2 dpf shows robust *gpr56* expression within the central nervous system (black arrows in **b**) during larval development (lateral views shown, anterior to the left, dorsal is up, two technical replicates performed). (**d**) Cross-section through the spinal cord (white dashed line in **c** depicts approximate location) of *gpr56* WISH embryo at 2 dpf shows *gpr56* expression in the spinal cord midline (white arrow) and in bands consistent with neural precursors (black arrows). (**e**) Diagram of the zebrafish *gpr56* gene (top) and protein (bottom) structures. TALENs used to generate *gpr56* zebrafish mutants targeted between the 8^th^ and 9^th^ exons (text in red). Gpr56 contains a signal sequence (ss), GPCR Autoproteolysis-Inducing Domain (GAIN), GPCR Proteolytic Site (GPS), and the canonical 7-Transmembrane Domain (7TM). (**f**) Recovered mutant alleles of *gpr56*--- *stl13* representing a 6 bp deletion and *stl14* representing a 26 bp deletion. (**g**) Amino acid sequence alignment of the GPS motif from representative species showing perfect conservation of the Trp residue that is deleted in the *gpr56^stl13/stl13^* allele (highlighted yellow). Mutation of the second, highly conserved Trp residue within the GPS causes BFPP (black arrowhead).](nihms649329f1){#F1}

![Oligodendrocyte development is impaired in *gpr56* zebrafish mutants\
(**a--b**) Representative fluorescent images of (**a**) control (*gpr56^stl13/+^*) and (**b**) *gpr56^stl13/13^* larvae at 28 hpf expressing *Tg(sox10(−7.2):memGFP)* to mark OPCs. (**c**) Quantification of OPC number (*sox10+*; white arrows) in control (*N=20*) and *gpr56^stl13/stl13^* (*N* =19) larvae. (**d-f**) Representative WISH images of the spinal cord of (**e**) *gpr56^stl13/stl13^* (*N=19*) and (**d**) control embryos (*gpr56^+/+^* and *gpr56^stl13/+^, N=22*) showing *nkx2.2a* expression to mark pro-OLs. **(f)** Quantification of pro-OL number (*nkx2.2a*+) (*p\<5.223×10^−6^*). (**g-j**) *mbp* expression (CNS marked by white arrow, hindbrain) in (**h**) *gpr56^stl13/13^* (*N= 20/27*), (**i**) *gpr56^stl14/stl14^*(*N=14/19*) and (**j**) MZ*gpr56^stl/13/stl13^*(5/5) larvae compared to (**g**) WT controls at 4 dpf (*N=13/13*). (**a-f**) All images and quantification thereof were taken from segments 5--6 for consistency. For (**a,b,d,e**) lateral views are shown, anterior to the left, dorsal is up; for (**g-j**) dorsal views are shown, anterior to the left. (**a-b**) Scale bar, 50 µm. (**d-e**) Scale bar, 100 µm. (**g-j**) Scale bar, 200 µm. Student's t-test used to test for statistical significance and error bars shown as ± s.d. A minimum of two technical replicates were performed for each marker. NS, not significant.](nihms649329f2){#F2}

![*gpr56* mutant spinal cord axons are hypomyelinated\
(**a**) Schematic representation of a 5 dpf zebrafish. Larvae were cut between segments 5 and 6 (red dashed line) and prepared for TEM. Axis shows orientation of the embryo (D, dorsal; V, ventral; A, anterior; P, posterior) (**b**) Diagram of a 5 dpf zebrafish cross-section, dorsal is up (D), ventral is down (V). In this image, the spinal cord is in orange and includes neuronal cell bodies (blue) and myelinated axons (green). Ventral region used for quantification is boxed in green, dorsal region used for quantification boxed in magenta. Muscle in purple. (**c-k**) Representative TEM images from the ventral spinal cord of WT (**c-e** *N=6*), *gpr56^stl13/stl13^* mutant larvae (**f-h**, *N=5*) and *gpr56^stl14/stl14^* mutant larvae (**i-k**, *N=4*) at 5 dpf. Higher magnifications of **c, f**, and **i** are shown in **d-e, g-h**, and **j-k**, respectively. (**c-d, f-g, i-j**) Myelinated axons are shaded green, unmyelinated large caliber axons (≥ 500 nm) are shaded orange. (**e, h, k**) Images from panels **d, g**, and **j** without pseudocolor. (**l**) Quantification of the percent of myelinated axons in the ventral spinal cord of *gpr56^stl13/stl13^* (*p\<.019*) and *gpr56^stl14/stl14^* (*p\<.039*) compared to WT controls. (**m**) Quantification of the total number of axonsin the ventral spinal cord of *gpr56^stl13/stl13^* (*p\<.5*) and *gpr56^stl14/stl14^* (*p\<.78*) compared to WT controls. (**n-o**) We also did not observe a significant difference in the number of myelin wraps per myelinated axon in mutants compared to control on the large caliber Mauthner axon (m) or on smaller caliber myelinated axons. (**c,f,i**) Scale bar, 1 µm. (**d-e, g-h, j-k**) Scale bar, 500 nm. (**l-o**) Quantification performed on a stereotyped 14 µm^2^ region (**b**) in the ventral spinal cord. Student's t-test used to test for statistical significance and error bars shown as ± s.d. NS, not significant. Data represents two technical replicates.](nihms649329f3){#F3}

![Loss of *Gpr56* does not affect neural precursor differentiation capacity\
Quantification of the percent of (**a**) GFAP+ astrocytes, (**b**) Nestin+ neural progenitors, (**c**) Tuj1+ neurons and (**d**) O4+ oligodendrocytes (per field of view) differentiated from neural precursors harvested from WT (*N=3*), *Gpr56+/−* (*N=4*), and *Gpr56−/−* (*N*=5) animals at postnatal day 3 (P3). Representative fluorescent images from each genotype shown to the right of each summary graph. Two-way ANOVA used to test for statistical significance and error bars shown as ± s.d. Data was acquired from two technical replicates.](nihms649329f4){#F4}

![*gpr56* mutant OPCs form premature associations with axons and are less proliferative than controls\
(**a-b**) Representative stills from *in vivo* time-lapse imaging of the spinal cord (white bracket at 16h) from segments 5--7 of (**a**) controls (*gpr56^stl13/+^, N=6*) and (**b**) *gpr56^stl13/stl13^* mutants (*N=7*) expressing *tg(sox10(−7.2):mRFP*) to visualize OPC behavior over time (three technical replicates performed). Embryos were imaged from 30 hpf to 46 hpf to encompass the transition of OPCs (white arrowheads) into pro-OLs (light green arrowheads). White arrows denote *sox10* expressing neural crest cells, and orange arrows mark the posterior lateral line nerve, which is part of the peripheral nervous system and is marked by the presence of migrating Schwann cell precursors. (**c**) Quantification of the number of pro-OL associated axons over time in *gpr56* mutants compared to controls at 30 hpf (*p\<.039*), 38 hpf (*p*\<.28),and 46 hpf (*p=.004*). (**d-f**) Representative TEM images of the ventral spinal cord of a WT (**d**, *N=3*) and *gpr56^stl13/stl13^* (**e-f**, *N=4*) embryo at 3 dpf (two technical replicates performed). (**e**) Additional non-Mauthner myelinated axons (shaded blue and numbered) were observed in *gpr56^stl13/stl13^* embryos (*p\<.048*) compared to controls. Mauthner axon shaded orange. (**f**) Image shows a higher magnification of panel **e** (green box). (**g**) Raw counts of non-Mauthner myelinated axons in control and *gpr56^stl13/stl13^* embryos at 3 dpf. (**h-j**) Representative fluorescent images of the spinal cord from segments 5--7 of (**h**) control (*gpr56^stl13/+^, N=31*) and (**i**) *gpr56^stl13/stl13^* mutant (*N=34*) embryos at 32 hpf (two technical replicates performed). Embryos expressing *tg(sox10 (−7.2):mRFP*) were fixed and stained with pH3 to assay proliferation. (**j**) Quantification of the number of proliferating OPCs in (**i**) *gpr56^stl13/stl13^* mutants compared to (**h**) controls (*p\<.0004*) (**k-m**) Quantification of dying cells (acridine orange +, one technical replicate per timepoint) in *gpr56^stl13/stl13^* mutants and controls (WT and *gpr56^stl13/+^*) at 32 hpf (control: *N=13, gpr56^stl13/stl13^: N=20*), 2 dpf (control: *N=21, gpr56^stl13/stl13^ N=12*) and 3 dpf (control: *N=19, gpr56^stl13/stl13^: N=20*). (**a-b, h-i**) Scale, 50 µm. (**d-e**) Scale, 1 µm. (**f**) Scale, 500 nm. Student's t-test used to test for statistical significance and error bars shown as ± s.d.](nihms649329f5){#F5}

![Overexpression of *gpr56* causes increased OPC number and inhibits myelination\
(**a-d**) WISH shows *nkx2.2a* expression in the spinal cord of injected WT larvae at 2.5 dpf. Lateral views are shown, dorsal is up. (**e-f**) Quantification of the number of *nkx2.2a*+ pro-OLs (black arrowheads) in WT embryos injected with 50 pg of synthetic *gpr56* mRNA (*N=30*) in the anterior (**b**, segments 5--6, *p\<8.7×10^−7^*) and posterior (**d**, segments 15--30, *p\<.01*) spinal cord compared to injected controls (**a, c**, *N=31*). (**g-j**) Representative images of a (**h, j**) *gpr56* injected WT larva (*N=19/31*) compared to a (**g, i**) control-injected embryo (*N=33/35*) showing *mbp* expression by WISH. **g-h**, lateral views shown, anterior on right. **i-j**, dorsal views shown, anterior on right. Black arrows, hindbrain. Black arrowheads, dorsal oligodendrocytes. White arrows, cranial nerves. (**k**) Cartoon of zebrafish larva in cross-section modified from [Fig. 3b](#F3){ref-type="fig"}. White box represents regions shown in **l-m, o-p**. Green box represents region shown in **r-u**. (**l-m, o-p**) Representative images of spinal cord cross-sections from 2.5 dpf (**l-m**) and 5 dpf (**o-p**) WT embryos injected with control (**l, o**) or 50 pg *gpr56* synthetic mRNA (**m, p**). 2.5 dpf: Scale, 500 nm. 5 dpf: Scale, 4 µm. (**n, q**) Quantification of the number of oligodendrocyte lineage cell-bodies (shaded purple) in *gpr56* injected embryos (*N=4*) compared to controls (*N=4*) at 2.5 dpf (*p\<.037*) and 5 dpf (*p\<.15, N=4* for controls and *N=5* for *gpr56* injected embryos). Neuronal cell bodies shaded green. (**r-u**) Representative TEM images of the spinal cord in cross-section from 5 dpf control (**r-s**) and *gpr56* injected (**t-u**) embryos. Scale, 1 µm. Quantification of total axon number (**v**), % myelinated axons (shaded blue, **w**, *p\<.05*) and myelin thickness on the large caliber Mauthner axon (shaded orange, **x**, *p\<.008*) in *gpr56* OE embryos at 5 dpf relative to controls. SC, spinal cord. Student's t-test used to test for statistical significance and error bars shown as ± s.d. Two technical replicates were performed for each overexpression experiment.](nihms649329f6){#F6}

![Manipulation of Gα~12/13~ and RhoA signaling influences CNS *mbp* expression in *gpr56* mutants\
(**a--d**) Injection of morpholinos (3MO) targeting Gα~12/13~ signaling (*gna12*-MO, *gna13a*-MO, and *gna13b*-MO, 1 ng each), constitutively active *rhoa* synthetic mRNA (10 pg), or phenol-red control yielded embryos with (**d**) WT, (**c**) reduced, (**b**) strongly reduced, or (**a**) nearly absent CNS *mbp* expression at 65 hpf by WISH (dorsal view shown, anterior is up, white arrows denote CNS *mbp* expression). We scored *mbp* expression as follows: 3 = WT, 2 = reduced, 1 = strongly reduced, 0 = nearly absent. (**e**) Phenotypic distribution by genotype and treatment (1 ng 3MO or control-injected). (**f**) Quantification of CNS *mbp* score by genotype and treatment (1 ng 3 MO or control-injected). (**f**) Respective p values: control WT versus control heterozygote: *p\< 0.077*; control WT versus control mutant: *p\<.0004*; 3MO-injected WT versus 3MO-injected heterozygote: *p\< 1.33×10^−05^*; 3MO-injected WT versus 3MO-injected mutant: *p\< 2.59×10^−6^*). (**i**) Phenotypic distribution by genotype and treatment (10 pg consitutively active RhoA (Rhov14) or control-injected) (**j**) Quantification of CNS *mbp* score by genotype and treatment (10 pg consitutively active RhoA (Rhov14) or control-injected). Respective p-values: control WT versus control mutant: *p\<.0009*; OE WT versus OE mutant: *p\<.343*. (**g-h, k-l**) All analyzed injected embryos were morphologically normal. Student's t-test used to test for statistical significance and error bars are shown as ± s.d. Two technical replicates were performed for the 3MO and the OE experiment. NS, not significant.](nihms649329f7){#F7}

![Gpr56 promotes OPC proliferation through inhibiting differentiation\
Model of Gpr56 function in OPCs. In WT OPCs, Gpr56 couples to Gα~12/13~ and activates RhoA, which prevents terminal differentiation and indirectly promotes OPC proliferation (dashed arrow) by maintaining the OPC in an immature, proliferative state. OPC proliferation is directly regulated via interactions between neuron-secreted PDGF-A and OPC bound PDGFRα. In Gpr56 (*stl13/stl13*) mutant OPCs, impaired autoproteolytic cleavage reduces Gpr56 signaling capacity, leading to loss of RhoA activation. Reduced RhoA signaling alleviates RhoA inhibition on terminal differentiation (green arrow), which indirectly causes a decrease in OPC proliferation (red dashed lines) as OPCs differentiate at the expense of proliferation.](nihms649329f8){#F8}
